Skip to main content
Affluent Medical logo

Affluent Medical — Investor Relations & Filings

Ticker · AFME ISIN · FR0013333077 LEI · 969500N30CO4B5N2GN67 PA Manufacturing
Open in API
Filings indexed 275 across all filing types
Latest filing 2026-03-19 Earnings Release
Country FR France
Listing PA AFME

About Affluent Medical

https://www.affluentmedical.com

Affluent Medical is a clinical-stage medical technology company that develops innovative, minimally invasive implants designed to restore essential physiological functions. The company's activities are concentrated in two primary therapeutic areas: structural heart disease and urology. It specifically addresses severe mitral valve insufficiency and urinary incontinence. The product pipeline, currently in clinical development, features three key devices: Kalios™, an adjustable annuloplasty ring for mitral valve repair; Epygon™, a biomimetic mitral valve for replacement procedures; and Artus™, an electronic artificial urinary sphincter for treating urinary incontinence. Affluent Medical's technologies are engineered to be adjustable and biomimetic, allowing for implantation via minimally invasive surgery and adaptation to both the patient's anatomy and the progression of their pathology.

Recent filings

Filing Released Lang Actions
Carvolix : Estimated full-year 2025 results.
Earnings Release Classification · 95% confidence The document is an announcement titled 'Estimated full-year 2025 results' for Carvolix. It provides key financial highlights, operational updates, and strategic milestones for the fiscal year 2025. It explicitly states that the full audited financial statements will be published later in a Universal Registration Document. Since this is an initial announcement of financial results (key highlights only) rather than the full annual report itself, it is classified as an Earnings Release. FY 2025
2026-03-19 English
Carvolix : Nombre d’actions composant le capital social et nombre total de droits de vote
Regulatory Filings Classification · 95% confidence The document is a formal regulatory disclosure required by Article L. 233-8 II of the French Commercial Code and Article 223-16 of the AMF General Regulation. It provides the total number of shares and voting rights for the company CARVOLIX as of February 28, 2026. This type of disclosure is a standard regulatory filing regarding capital structure and voting rights, which does not fit into specific categories like M&A, dividends, or director dealings, making 'RNS' (Regulatory Filings) the most appropriate classification.
2026-03-03 French
Carvolix : Nombre dactions composant le capital social et nombre total de droits de vote
Regulatory Filings Classification · 95% confidence The document is a regulatory announcement from Carvolix (Affluent Medical) regarding the total number of shares and voting rights as of February 28, 2026. This is a standard periodic disclosure required by the French Autorité des Marchés Financiers (AMF) under Article L. 233-8 II of the Commercial Code. Since this is a specific regulatory disclosure regarding capital structure and voting rights that does not fit into categories like 'Share Issue' (which implies a change event) or 'Major Shareholding' (which implies a third-party notification), it is best classified as a general Regulatory Filing (RNS).
2026-03-03 French
Franchissement de seuils
Major Shareholding Notification Classification · 100% confidence The document is an official notice from the Autorité des Marchés Financiers (AMF) regarding a 'Déclaration de franchissement de seuils' (Declaration of crossing thresholds). This specifically refers to a major shareholder notifying the market that they have crossed a significant ownership percentage (2/3 of capital and voting rights) in the company CARVOLIX. This aligns perfectly with the definition of a Major Shareholding Notification.
2026-02-17 French
Carvolix : Nombre d’actions composant le capital social et nombre total de droits de vote au 31.01.26.
Share Issue/Capital Change Classification · 95% confidence The document is a regulatory disclosure required by French law (Article L. 233-8 II of the Commercial Code and Article 223-16 of the AMF General Regulation) regarding the total number of shares and voting rights. This type of filing is a standard periodic regulatory update concerning capital structure and voting rights, which falls under the 'Regulatory Filings' (RNS) category as it does not represent a specific corporate event like a dividend declaration, share buyback, or major shareholding notification.
2026-02-06 French
Carvolix : Nombre dactions composant le capital social et nombre total de droits de vote au 31.01.26.
Share Issue/Capital Change Classification · 95% confidence The document is a regulatory announcement from Carvolix (Affluent Medical) regarding the total number of shares and voting rights as of January 31, 2026. This is a standard periodic disclosure required by the French Autorité des Marchés Financiers (AMF) under Article L. 233-8 II of the Commercial Code. While it provides specific data, it is a regulatory disclosure announcement rather than a comprehensive financial report or a capital change event (like a new share issuance). Given the specific nature of this disclosure, it falls under the 'Regulatory Filings' (RNS) category as it is a mandatory periodic regulatory update.
2026-02-06 French

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.